drugset / Trial / NCT06015022
EGCG for Hepatocellular Carcinoma Chemoprevention
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epigallocatechin gallate | Small molecule | 600 mg | Oral |
| Subject | Epigallocatechin gallate | Small molecule | 800 mg | Oral |